STEQEYMA Q Code: Q5099

Self-Administered Drug Exclusion 7 Medicare Administrative Contractors list Q5099 as usually self-administered and exclude it from Part B coverage in their jurisdictions. Check the article for your MAC before billing: CGS, First Coast, Noridian (A53032), Noridian (A53033), Novitas, Palmetto, Wellpoint Federal, WPS · All SAD lists →

Drug & Product Overview

HCPCS Descriptor Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg

HCPCS Added Date July 1, 2025

Manufacturer Celltrion USA

Route of Administration Intravenous, Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About STEQEYMA

Steqeyma is a medication aligned to the HCPCS Q Code: Q5099 for billing, pricing, and reimbursement purposes in the United States. This Immunology medication is administered via the intravenous or subcutaneous routes and manufactured by Celltrion USA.

According to CMS Drug Use Information: Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative colitis). It works by blocking certain natural proteins in your body (interleukin-12 and interleukin-23) that cause inflammation (swelling) in these conditions. Ustekinumab does not cure these diseases, but helps to lessen symptoms of the disease. It can help to decrease the amount of plaques in plaque psoriasis, decrease the number of swollen/painful joints in psoriatic arthritis, and decrease symptoms such as abdominal pain/cramping and diarrhea in Crohn's disease and ulcerative colitis. This monograph is about the following ustekinumab products: ustekinumab, ustekinumab-aauz, ustekinumab-aekn, ustekinumab-auub, ustekinumab-hmny, ustekinumab-kfce, ustekinumab-srlf, ustekinumab-stba, ustekinumab-ttwe.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
72606-0027-01	Steqeyma	CELLTRION USA, Inc.	45	45 MG / 0.5 ML
72606-0028-01	Steqeyma	CELLTRION USA, Inc.	90	90 MG / 1 ML
72606-0029-01	Steqeyma	CELLTRION USA, Inc.	130	130 MG / 26 ML
72606-0060-01	Steqeyma	CELLTRION USA, Inc.	45	45 MG / 0.5 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

STEQEYMA Pricing & Reimbursement

Q5099 Private Payer Reimbursement

$12.17 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q4 2026

Ustekinumab Biosimilar Information:

STEQEYMA Approval Date: December 17, 2024

Product Name	HCPCS Code	Active Ingredient	BLA Type
Stelara	J3358	Ustekinumab	351(a) Originator Product
Imuldosa	Q5098	Ustekinumab	351(k) Interchangeable
Steqeyma	Q5099	Ustekinumab	351(k) Interchangeable
Yesintek	Q5100	Ustekinumab	351(k) Interchangeable
Wezlana	Q5137	Ustekinumab	351(k) Interchangeable
Wezlana	Q5138	Ustekinumab	351(k) Interchangeable
Starjemza	Q5164	Ustekinumab	351(k) Interchangeable
Pyzchiva	Q9996	Ustekinumab	351(k) Interchangeable
Pyzchiva	Q9997	Ustekinumab	351(k) Interchangeable
Selarsdi	Q9998	Ustekinumab	351(k) Interchangeable
Otulfi	Q9999	Ustekinumab	351(k) Interchangeable

STEQEYMA CPT Administration Codes

CPT Code	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96401 Login for More	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic Login for More

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

STEQEYMA Medically Unlikely Edits (MUE)

The most billing units of Q5099 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

520 units / day

= 520 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

STEQEYMA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Crohn's Disease Plaque Psoriasis Psoriatic Arthritis Ulcerative Colitis

Drug Class

Interleukin-12 Antagonist [EPC]Interleukin-12 Antagonists [MoA]Interleukin-23 Antagonist [EPC]Interleukin-23 Antagonists [MoA]

Frequently Asked Questions

Is there an available STEQEYMA billing and coding guide?

Billing and coding information for STEQEYMA can be found through Celltrion USA Inc.. Visit Here →

Are there any available STEQEYMA patient assistance programs?

STEQEYMA patient assistance information can be found through Celltrion USA Inc.. Visit Here →

Where can I find STEQEYMA prescribing information?

STEQEYMA prescribing information can be found at the link below. Visit Here →

Where can I find STEQEYMA side effect information?

We have not identified a source of side effect information for STEQEYMA.

Does billing STEQEYMA require JZ/JW wastage modifiers?

CMS does not include STEQEYMA (Q5099) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5099. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.